Comparison of activity levels of cytokine in serum of patient with pancreatic cancer and validation of clinical effects
- Conditions
- Neoplasms
- Registration Number
- KCT0004614
- Lead Sponsor
- Yonsei University Health System, Gangnam Severance Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 510
1. Pancreatic cancer
1). Patients with pancreatic cancer confirmed by imaging (CT, MRI, PET-CT)
2). Patients with pancreatic cancer diagnosed using cytology by endoscopic ultrasound
3). Patients who underwent surgical treatment with pancreatic cancer
2. Patients with other carcinomas (biliary cancer, stomach cancer, liver cancer, colon cancer, lung cancer)
1) Biliary cancer: Patients suspected of biliary tract cancer by imaging tests (CT, MRI, PET-CT) and biliary endoscopic examination and confirmed biliary tract cancer by tissue or cytology examination
2) Stomach cancer: Patients suspected of stomach cancer by imaging tests (CT, MRI, PET-CT) and endoscopic examination and confirmed stomach cancer by tissue or cytology examination
3) Liver cancer: Patients suspected of liver cancer by imaging tests (CT, MRI, PET-CT) and confirmed liver cancer by tissue or cytology examination
4) Colorectal cancer: Patients with colorectal cancer suspected by imaging tests (CT, MRI, PET-CT), and colonoscopy and confirmed colorectal cancer by tissue or cytology examination
5) Lung cancer: Patients whose lung cancer is suspected by imaging tests by imaging tests (X-ray, CT, MRI, PET-CT), sputum cell test, and bronchoscope and confirmed lung cancer by tissue or cytology examination
3. Patients with high risk for pancreatic cancer
Patient diagnosed with ? chronic pancreatitis ? pancreatic cyst ? benign pancreatic mass ? pancreatic duct dilatation by imaging studies (US, CT, MRI) ? Patients diagnosed with diabetes within two years of age 55 and older ? Patients with elevated CA 19-9 levels (50U / mL or higher; normal reference value: 0.8-24 U / mL)
4. Patients with benign pancreatic disease
Patient diagnosed with acute pancreatitis
5. healthy control
Those who have not been diagnosed with malignant or pancreatic diseases through a medical examination within 6 months of the decision to participate in the study
1. Minors under the age of 19, vulnerable subjects such as illiteracy
2. Those who have received immunosuppressive drugs from past medical history
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparative evaluation of cytokine expression in serum of pancreatic cancer patients, other carcinomas (biliary cancer, gastric cancer, liver cancer, colon cancer, lung cancer), patients with high risk of pancreatic cancer, patients with benign pancreatic disease and normal subjects
- Secondary Outcome Measures
Name Time Method Evaluation of cytokine expression as a factor predicting pancreatic cancer diagnosis and prognosis